Generics in Spain

Generics in Spain

Summary

Generics in Spain industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

  • A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
  • The Spanish generics market recorded revenues of $4 billion in 2023, representing a compound annual growth rate (CAGR) of 3.1% between 2018 and 2023.
  • Market consumption volume increased with a CAGR of 1% between 2018 and 2023, to reach a total of 41.3% of total pharma volume in 2023.
  • According to GlobalData, in 2023, the Spanish generics market grew by 3.5% annually. The growth is attributed to the country’s mounting aging population. According to the United States Census Bureau, in 2023, the population aged 65 years and above in Spain reached 9.9 million, up 3.3% over 2022.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Spain
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Spain
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Spain generics market with five year forecasts by both value and volume
Reasons to Buy
  • What was the size of the Spain generics market by value in 2023?
  • What will be the size of the Spain generics market in 2028?
  • What factors are affecting the strength of competition in the Spain generics market?
  • How has the market performed over the last five years?
  • Who are the top competitors in Spain's generics market?


1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths of the leading player?
7.3. What are the challenges in the market?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Ltd
8.2. Viatris Inc
8.3. Esteve Pharmaceuticals SA
8.4. Novartis AG
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine
List of Tables
Table 1: Spain generics market value: $ million, 2018-23
Table 2: Spain generics market volume: % of total pharma volume, 2018-23
Table 3: Spain generics market geography segmentation: $ million, 2023
Table 4: Spain generics market value forecast: $ million, 2023-28
Table 5: Spain generics market volume forecast: % of total pharma volume, 2023-28
Table 6: Teva Pharmaceutical Industries Ltd: Key Facts
Table 7: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Ltd: Key Employees
Table 9: Viatris Inc: Key Facts
Table 10: Viatris Inc: Annual Financial Ratios
Table 11: Viatris Inc: Key Employees
Table 12: Esteve Pharmaceuticals SA: Key Facts
Table 13: Esteve Pharmaceuticals SA: Key Employees
Table 14: Novartis AG: Key Facts
Table 15: Novartis AG: Annual Financial Ratios
Table 16: Novartis AG: Key Employees
Table 17: Spain Size of Population (million), 2019-23
Table 18: Spain Real GDP (Constant 2010 Prices, $ Billion), 2019-23
Table 19: Spain GDP (Current Prices, $ Billion), 2019-23
Table 20: Spain Inflation, 2019-23
Table 21: Spain Consumer Price Index (Absolute), 2019-23
Table 22: Spain Exchange Rate, 2018-23
List of Figures
Figure 1: Spain generics market value: $ million, 2018-23
Figure 2: Spain generics market volume: % of total pharma volume, 2018-23
Figure 3: Spain generics market geography segmentation: % share, by value, 2023
Figure 4: Spain generics market value forecast: $ million, 2023-28
Figure 5: Spain generics market volume forecast: % of total pharma volume, 2023-28
Figure 6: Forces driving competition in the generics market in Spain, 2023
Figure 7: Drivers of buyer power in the generics market in Spain, 2023
Figure 8: Drivers of supplier power in the generics market in Spain, 2023
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Spain, 2023
Figure 10: Factors influencing the threat of substitutes in the generics market in Spain, 2023
Figure 11: Drivers of degree of rivalry in the generics market in Spain, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings